Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited

Country	Switzerland
Founded	2000
IPO Date	Oct 2, 2015
Industry	Medical Devices
Sector	Healthcare
Employees	1,488
CEO	Ashley Cordova

Contact Details

Address: Neuhofstrasse 21 Baar, 6340 Switzerland
Website	novocure.com

Stock Details

Ticker Symbol	NVCR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001645113
CUSIP Number	G6674U108
ISIN Number	JE00BYSS4X48
SIC Code	3841

Key Executives

Name	Position
Ashley Cordova	Chief Executive Officer and Director
William F. Doyle	Executive Chairman
Barak Ben-Arye	General Counsel
Dr. Uri Weinberg M.D., Ph.D.	Chief Innovation Officer
Frank Leonard	Executive Vice President and President of Novocure Oncology
Christoph Brackmann	Chief Financial Officer
Mukund Paravasthu	Chief Operating Officer
Ingrid Goldberg	Vice President of Investor Relations
Michael Puri	Chief Human Resources Officer
Dr. Nicolas Leupin M.B.A., M.D., Ph.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
May 5, 2025	144	Filing
Apr 24, 2025	8-K	Current Report
Apr 24, 2025	10-Q	Quarterly Report
Apr 23, 2025	SCHEDULE 13G/A	Filing
Apr 22, 2025	8-K	Current Report
Apr 21, 2025	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 21, 2025	DEF 14A	Other definitive proxy statements
Apr 1, 2025	SCHEDULE 13G	Filing
Mar 3, 2025	144	Filing
Mar 3, 2025	144	Filing

View All SEC Filings